Candel Therapeutics, Inc. (CADL)
| Market Cap | 706.33M +170.3% |
| Revenue (ttm) | n/a |
| Net Income | -54.42M |
| EPS | -0.97 |
| Shares Out | 73.27M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,158,238 |
| Open | 9.91 |
| Previous Close | 9.87 |
| Day's Range | 9.59 - 9.98 |
| 52-Week Range | 4.35 - 11.36 |
| Beta | -0.51 |
| Analysts | Strong Buy |
| Price Target | 20.29 (+110.48%) |
| Earnings Date | Aug 13, 2026 |
About CADL
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery pl... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for CADL stock is "Strong Buy." The 12-month stock price target is $20.29, which is an increase of 110.48% from the latest price.
News
Candel Therapeutics initiated with a Buy at Stifel
Stifel analyst Stephen Willey initiated coverage of Candel Therapeutics (CADL) with a Buy rating and $22 price target The firm views the company’s aglatimagene as a “differentiated” and “versatile” lo...
Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEEDHAM, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunoth...
Candel Therapeutics Slides: Corporate presentation
Candel Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 7, 2026.
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEEDHAM, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunoth...
Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
NEEDHAM, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunoth...
Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer
NEEDHAM, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunoth...
Candel Therapeutics Transcript: AGM 2026
The meeting confirmed a quorum and approved all proposals, including the election of four directors for a three-year term and the ratification of KPMG LLP as auditor for 2026. Voting results will be included in official filings.
Candel Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Lead viral immunotherapies showed strong efficacy in prostate cancer and glioblastoma, with aglatimagene achieving significant improvements in disease-free survival and linoserpaturev doubling median survival in recurrent glioblastoma. Financial runway extends into 2028, with key regulatory filings and new trials planned this year.
Candel Therapeutics publishes pivotal Phase 3 data for Aglatimagene
Candel Therapeutics (CADL) announced the publication of results from its pivotal Phase 3 trial of Aglatimagene in The Lancet Oncology. The trial, which enrolled 745 patients with intermediate- to high...
Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
NEEDHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunoth...
Candel Therapeutics Transcript: Stifel 2026 Targeted Oncology Virtual Forum
Viral immunotherapy aglatimagene showed significant improvement in disease-free survival for localized prostate cancer, with strong support from key opinion leaders and a large market opportunity. BLA submission is on track for year-end, and a phase III lung cancer trial will soon begin.
Candel Therapeutics price target raised to $9 from $7 at BofA
BofA analyst Alec Stranahan raised the firm’s price target on Candel Therapeutics (CADL) to $9 from $7 and keeps a Neutral rating on the shares. Candel’s update for aglatimagene in…
Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting
NEEDHAM, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunothe...
Candel Therapeutics Transcript: Study result
Extended follow-up from a phase III trial in intermediate to high-risk localized prostate cancer showed aglatimagene plus radiotherapy significantly improved disease-free survival, reduced metastasis, and delayed need for salvage therapy, with favorable safety and strong expert endorsement for rapid clinical adoption.
Candel Therapeutics Slides: Study result
Candel Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 15, 2026.
Candel Therapeutics Press release: Study result
Candel Therapeutics issued a press release on May 15, 2026, disclosing material business information to investors.
Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
NEEDHAM, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunothe...
Candel Therapeutics Earnings release: Q1 2026
Candel Therapeutics released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Candel Therapeutics Quarterly report: Q1 2026
Candel Therapeutics has published its Q1 2026 quarterly earnings report on May 14, 2026.
Candel Therapeutics Slides: Corporate presentation
Candel Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 14, 2026.
Candel Therapeutics to Present at Upcoming Investor Conferences
NEEDHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunoth...
Candel Therapeutics Slides: Corporate presentation
Candel Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
NEEDHAM, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunothe...
Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer
EVERSANA, a purpose-built, partner-led commercial organization, positions Candel for potential U.S. commercial launch following planned BLA submission in Q4 2026
Candel Therapeutics Proxy statement: Proxy filing
Candel Therapeutics filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.